David H. Crean, PhD, Managing Director and head of our Life Sciences and Healthcare Practice Group provides his thoughts and guidance to entrepreneurs, founders and business owners in the life sciences sector on what he has seen as successful pitches to investors and strategic companies in the initial pitches of their company and technology. By providing as much of the information noted below during the process, we believe that you can improve the probability and chances of landing a transaction that supports company growth or exit strategies. David has also previously authored related articles on this topic that can be viewed here and here. Happy to clarify any topic if needed.(more…)
San Diego, CA and Flagstaff, AZ, April 12, 2018: — Symple Surgical, Inc., a privately-held, early-stage medical device company focused on developing novel therapeutic technologies using microwave technology for treatment of life-threatening chronic conditions, is pleased to the announce that they have retained Objective Capital Partners as their exclusive financial advisor. Objective Capital Partners, a middle-market Investment Banking firm located in Southern California and focused on mergers & acquisitions (M&A), strategic advisory, capital financing and valuation services, will seek to identify strategic partnerships and financial investors for the Company to progress their lead product Grizzly™ targeting pre-cancerous cells in the elimination of Barrett's Esophagus and Esophageal Adenocarcinoma, the fastest growing cancer worldwide.
Barrett’s Esophagus (BE) is a premalignant condition caused by stomach acid or gastrointestinal reflux disease (GERD) mutating healthy cells in the lower esophagus into Barrett’s cells. Approximately 90% of Esophageal Adenocarcinoma (EAC) patients do not receive a prior diagnosis of Barrett’s Esophagus (BE). BE affect’s more than 12 million American adults, and is associated with a 30-fold increased risk of developing EAC. This new treatment will provide an alternative to the Radiofrequency Ablation Technology (“RFA”) and cryoablation technologies currently in use for treatment of BE thereby reducing the number of episodes of treatment and providing unparalleled user control for adequate cell removal.(more…)
San Diego, April 9, 2018 — Objective Capital Partners is pleased to announce the promotion of Michael Kim to Managing Director. Michael contributes over 15 years of mergers & acquisitions (M&A) and corporate finance experience across numerous industries including technology, consumer, and business services. He was also recognized in 2016 by M&A Advisor as a M&A Advisor Emerging Leaders Award Winner.
Mr Kim joined Objective Capital in 2015 and has been responsible for all aspects of transaction lifecycle including client sourcing, due diligence, negotiation, valuation analyses, and transaction closings. In his new role, Michael will continue serving the firm’s clients in the areas of transaction origination, analysis and execution.(more…)
San Diego Business Journal Health Care Heros Award
San Diego, March 1, 2018 – The San Diego Business Journal’s 2018 Health Care Heroes Awards chose Objective Capital Partners’ David H. Crean, Ph.D. from among the finalists to receive the Health Care Hero Award for Company Executive for his role in healthcare innovation and support.
Leading Objective Capital Partners’ Life Sciences & Healthcare Investment Banking Practice, David leverages more than 20 years of life sciences R&D and corporate development experience. In his Managing Director role, David helps companies secure growth capital, establish strategic partnerships, and achieve exit transactions.(more…)
The Alliance of Merger & Acquisition Advisors® (AM&AA)
San Diego, January 30, 2018 — Objective Capital Partners, a middle-market M&A Advisory Firm located in Southern California, is pleased to announce that David H. Crean, Ph.D., Managing Director of the firm’s thriving Life Sciences and Healthcare practice, has been selected as the winner of the 2017 Thought Leader of the Year Award by The Alliance of Merger & Acquisition Advisors® (AM&AA).
The AM&AA recognized that “David’s thought leadership is materially expanding the investment banker’s role in serving life sciences companies and providing these companies with a highly attractive, non-diluting alternative to hard-to-secure venture capital financing.”
“We are observing life sciences and healthcare companies increasing engaging specialized investment banking teams with deep industry experience to gain a strategic advantage,” said Trever Acers, Managing Director at Objective Capital Partners. “Specialized professionals such as David and his team members at Objective Capital are engaged by experienced Life Sciences executives to significantly improve the value, probability and speed of their M&A, strategic partnering, and growth capital objectives. David is at the forefront of this change, leveraging his decades of industry experience with best-in-class investment banking capabilities to provide CEO with highly actionable strategic guidance."(more…)
San Diego, CA- January 23, 2018 – Objective Capital Partners, a middle-market M&A Advisory Firm located in Southern California, is pleased to announce that Trever Acers, a Managing Director at the firm, will be presenting at a series of monthly Community Insights alongside Greg Banner, Vice President at Asset Preservation Strategies. This series of discussions is targeted towards business owners to help them understand planning options for their business. The Community Insights series is designed to introduce estate, financial, business, real estate as well as long-term care planning clients to the various options that facilitate achieving their goals.
There is no cost to attend the Community Insights series but you must register online at:(more…)
San Diego, CA- December 18, 2017 – Objective Capital Partners, a middle-market M&A Advisory Firm located in Southern California, is pleased to announce that Trever Acers, a Managing Director at the firm, has been recognized by the San Diego Business Journal in the 2018 edition of the San Diego 500, The Book of Influential Business Leaders. The publication’s editorial team selected the honorees from every sector of the San Diego Business community.(more…)
San Diego, December 12, 2017 — Objective Capital Partners, a middle market M&A Advisory Firm located in Southern California, is pleased to announce that David H. Crean, Ph.D., one of its Managing Directors who heads its thriving life science and healthcare practice, has been selected as top five national finalist for the 2017 Thought Leader of the Year Award by The Alliance of Merger & Acquisition Advisors® (AM&AA). For more information on the Award and the Finalists, please visit http://www.amaaonline.com/thought-leader-of-the-year/(more…)
Objective Capital Partners has expertise in four industry sectors: Business Services, Consumer, Life Sciences & Healthcare, and Technology. As part of our ongoing efforts in the Life Sciences and Healthcare space, we have developed specific expertise in Life Science Tools. In fact, we recently closed an interesting transaction in the life sciences services space.(more…)
Objective Capital’s David H. Crean to Serve as Guest Panelist at LaunchBio Event, November 14, 2017
San Diego, November 9, 2017 — Objective Capital Partners, a middle market M&A Advisory Firm located in Southern California, is pleased to announce that David H. Crean, Ph.D., one of its Managing Directors who heads its thriving life science and healthcare practice, has been invited to speak as a guest panelist at LaunchBio Series Event for life science companies entitled BIO Buck$ Fast Forward: A Start-ups Guide to Investment Banks. Dr. Crean will be joined by Charlie Adams, Cantor Fitzgerald and Tony Grover, VP of Business Development at Banyan Biomarker.(more…)
This article is provided for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC makes no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person.